Role of the NF1 gene in leukemogenesis and myeloid growth control

Journal of Pediatric Hematology/Oncology

Volumn 19, Issue 6, 1997, Pages 551-554

  O'Marcaigh, Aengus S ^a   Shannon, Kevin M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROFIBROMIN;

AUTOSOMAL DOMINANT DISORDER; BONE MARROW CELL; CELL GROWTH; GENETIC REGULATION; GROWTH REGULATION; HUMAN; HUMAN CELL; LEUKEMOGENESIS; NEUROFIBROMATOSIS; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; DISEASE MODELS, ANIMAL; GENES, NEUROFIBROMATOSIS 1; HUMANS; LEUKEMIA; LEUKEMIA, EXPERIMENTAL; LEUKEMIA, MYELOID; MICE;

EID: 0031424378     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199711000-00015     Document Type: Review

References (27)

1. Riccardi VM, Eichner JE. Neurofibromatosis. Baltimore: Johns Hopkins University Press, 1986.
2. Castro-Malaspina H, Schaison G, Passe S, et al. Subacute and chronic myelomonocytic leukemia in children (juvenile CML). Cancer 1984;54:675-86.
3. Passmore SJ, Hann IM, Stiller CA, et al. Pediatric myelodysplasia: a study of 68 children and a new prognostic scoring system. Blood 1995;85:1743-9.
4. Shannon KM, Watterson J, Johnson P, et al. Monosomy 7 myeloproliferative disease in children with neurofibromatosis, type 1: epidemiology and molecular analysis. Blood 1992;79:1311-8.
5. Stiller CA, Chessells JM, Fitchett M. Neurofibromatosis and childhood leukemia/lymphoma: a population-based UKCCSG study. Br J Cancer 1994;70:969-72.
6. Luna-Fineman S, Shannon K, Lange BJ. Childhood monosomy 7: epidemiology, biology and mechanistic implications. Blood 1995;85:1985-99.
7. Jacks T, Shih S, Schmitt EM, et al. Tumorigenic and developmental consequences of a targeted Nf1 mutation in the mouse. Nature Genet 1994;7:353-61.
8. Largaespada DA, Brannan CI, Jenkins NA, et al. Nf1 deficiency causes Ras-mediated granulocyte-macrophage colony stimulating factor hypersensitivity and chronic myeloid leukemia. Nature Genet 1996;12:137-43.
9. Shannon KM, O'Connell P, Martin GA, et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med 1994;330:597-601.
10. Miles DK, Freedman MH, Stephens K, et al. Patterns of hematopoietic lineage involvement in children with neurofibiomatosis, type 1, and malignant myeloid disorders. Blood 1996;88:4314-20.
11. Side L, Taylor B, Cayouette M, et al. Homozygous inactivation of NF1 in the bone marrows of children with neurofibromatosis, type 1 and malignant myeloid disorders. N Engl J Med 1997;336:1713-20.
12. Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: a conserved switch for diverse cell functions. Nature 1990;348:125-32.
13. Hall A. The cellular functions of small GTP-binding proteins. Science 1990;249:635-40.
14. Rodenhuis S. ras and human tumors. Semin Cancer Biol 1992;3(4):241-7.
15. Pierce JH, Aaronson SA. Myeloid cell transformation by ras-containing murine sarcoma viruses. Mol Cell Biol 1985;5(4):667-74.
16. Boguski M, McCormick F. Proteins regulating Ras and its relatives. Nature 1993;366:643-53.
17. Bader JL, Miller RW. Neurofibromatosis and childhood leukemia. J Pediatr 1978;92:925-9.
18. Gadner H, Haas OA. Experience in pediatric myelodysplastic syndromes. Hematol Oncol Clin North Am 1992;6:655-72.
19. Weinberg RA. Tumor suppressor genes. Science 1991;254:1138-46.
20. ras Blood 1994;84:3435-9.
21. Bollag G, Clapp DW, Shih S, et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in murine and human hematopoietic cells. Nature Genet 1996;12:144-8.
22. Gualtieri RJ, Emanuel PD, Zuckerman KS, et al. Granulocytemacrophage colony-stimulating factor is an endogenous regulator of cell proliferation in juvenile chronic myelogenous leukemia. Blood 1989;74:2360-7.
23. Freedman MH, Cohen A, Grunberger T, et al. Central role of tumor necrosis factor, GM-CSF, and interleukin 1 in the pathogenesis of juvenile chronic myelogenous leukemia. Br J Haematol 1992;80:40-8.
24. Emanuel PD, Bates LJ, Castleberry RP, et al. Seletive hypersensitivity to granulocyte-macrophage colony stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood 1991;77:925-9.
25. Iversen P, Rodwell RL, Pitcher L, et al. Inhibition of proliferation and induction of apoptosis in JMML cells by the granulocytemacrophage colony-stimulating factor analogue E21R. Blood 1996;88:2635-9.
26. Gibbs JB, Oliff A, Kohl NE. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 1994;77:175-8.
27. Kohl NE, Omer CA, Conner MW, et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nature Med 1995;1(8):792-7.